Pfizer’s Covid-19 vaccine is more than 90% effective, suggests data

Although Pfizer announces positive results of its vaccine trials, the vaccine might not be suitable for Pakistan, according to Chairman of Prime Minister’s Taskforce on Science and Technology Dr. Atta ur Rehman


By Cutacut Editorial Team

KARACHI: The world celebrates as Pfizer takes the lead in the global race to find an effective vaccine against the novel Coronavirus. One of the world’s most renowned drugmakers, Pfizer gave the world the good news of being able to finally develop the vaccine it had been waiting for this Monday. The vaccine is robust against the novel Coronavirus and shows more than 90% effectiveness. This is an extremely promising development to a world that lost about 1.2 million people to the coronavirus pandemic.

According to New York Times, Pfizer has worked alongside the German drugmaker BioNTech, and only sparse details have been released from the first clinical trial of the vaccine after a formal review of data by a panel of experts from outside.

Pfizer plans on asking the Food and Drug Administration for emergency authorization of the two-dose vaccine after collecting the recommended safety data of two months. According to its executives, by the end of 2020, the company plans on manufacturing enough vaccines that can immunize 15-20 million people.

“This is a historical moment,” said Kathrin Jansen, a senior vice president and the head of vaccine research and development at Pfizer.

 

View this post on Instagram

 

A post shared by Pfizer Inc. (@pfizerinc)

While the news has been groundbreaking, Dr. Atta Ur Rehman, Chairman of Prime Minister’s Taskforce on Science and Technology believes it is too early for Pakistan to celebrate. Pakistan had re-emerged from its first lockdown, only to see a surge in its coronavirus cases recently.

“This vaccine is not suitable for Pakistan in my opinion,” he told Geo Pakistan on Tuesday.

“The first problem is that the FDA has not given the approval, the regulatory bodies have to approve, and will take two months.” He explained how the regulatory bodies will first have to see the results and then allow the company to finalize their vaccine.

He also highlighted that the vaccine requires temperatures as low as -80 °C. Making sure this temperature stays within the containment of the vaccine is a major problem for third-world countries like Pakistan. The former HEC chairman also pointed out how third-world countries like Pakistan also do not have the ‘cold chain’ that will allow them to transport the vaccine keeping its temperature at -80°C temperatures from the suppliers all the way to the hospitals.

The vaccine must also be taken in two doses, which according to him makes it unreliable. “The third biggest problem is that you do not know how many days it is effective,” said Dr. Rehman. He said that at the given moment, no “evidence, or any result” has been seen by Pfizer and BioNtech to determine its effectiveness.

 

Read More